| PS (PRP + SHAM) | PE (PRP + ESWT) | p-value* |
---|---|---|---|
IL-33 | |||
 Before treatment | 1.44 ± 0.5 | 0.69 ± 0.24 | > 0.05 |
 After treatment | 4.61 ± 1.67 | 1.70 ± 0.68 | > 0.05 |
 p-value# |  > 0.05 |  > 0.05 |  |
IL-17 | |||
 Before treatment | 0.06 ± 0.02 | 0.09 ± 0.02 | > 0.05 |
 After treatment | 0.15 ± 0.04 | 0.14 ± 0.03 | > 0.05 |
 p-value | < 0.05 | < 0.05 |  |
IL-6 | |||
 Before treatment | 1.15 ± 0.13 | 1.71 ± 0.39 | > 0.05 |
 After treatment | 1.97 ± 0.34 | 1.32 ± 0.25 | 0.031 |
 p-value | < 0.05 | > 0.05 |  |
IL-15 | |||
 Before treatment | 19.07 ± 7.32 | 7.70 ± 1.41 | > 0.05 |
 After treatment | 19.22 ± 6.02 | 11.15 ± 1.47 | > 0.05 |
 p-value | > 0.05 | < 0.05 |  |
VEGF-A | |||
 Before treatment | 244.70 ± 45.47 | 218.00 ± 33.74 | > 0.05 |
 After treatment | 220.55 ± 44.54 | 226.04 ± 34.97 | > 0.05 |
 p-value | < 0.05 | > 0.05 |  |